Celldex Therapeutics (NASDAQ:CLDX) Price Target Lowered to $48.00 at Wells Fargo & Company

Posted by Stanley Muller on Jul 22nd, 2026

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its price target dropped by research analysts at Wells Fargo & Company from $54.00 to $48.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price would indicate a potential upside of 38.55% from the stock’s previous close.

Several other research firms have also issued reports on CLDX. Cantor Fitzgerald dropped their price target on shares of Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a research report on Wednesday. UBS Group lifted their price objective on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. HC Wainwright reaffirmed a “buy” rating and issued a $42.00 target price on shares of Celldex Therapeutics in a report on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Friday. Finally, Guggenheim lifted their price target on Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $52.77.

View Our Latest Analysis on Celldex Therapeutics

Celldex Therapeutics Trading Down 2.8%

Shares of NASDAQ:CLDX traded down $1.01 during trading on Wednesday, hitting $34.65. 1,037,650 shares of the company were exchanged, compared to its average volume of 963,039. The stock has a market cap of $2.72 billion, a price-to-earnings ratio of -8.11 and a beta of 0.90. Celldex Therapeutics has a fifty-two week low of $19.72 and a fifty-two week high of $40.30. The firm has a fifty day moving average price of $33.46 and a two-hundred day moving average price of $30.53.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.80 million. As a group, research analysts predict that Celldex Therapeutics will post -4.36 EPS for the current year.

Hedge Funds Weigh In On Celldex Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CLDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 680 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Celldex Therapeutics by 327.3% during the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock worth $7,259,000 after buying an additional 306,330 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Celldex Therapeutics by 12.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock worth $2,383,000 after buying an additional 14,979 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the period. Finally, Hsbc Holdings PLC acquired a new position in Celldex Therapeutics in the 2nd quarter valued at about $347,000.

Key Headlines Impacting Celldex Therapeutics

Here are the key news stories impacting Celldex Therapeutics this week:

Negative Sentiment: Celldex announced that its Phase 2 study of barzolvolimab in prurigo nodularis failed to meet the main goal and key secondary goals, prompting the company to stop development of the program. Celldex to stop skin disease study after trial setback
Negative Sentiment: Investors also reacted to after-hours weakness tied to the trial setback, with reporting pointing to a sharp selloff in CLDX following the data release. CLDX stock down 10% after-hours — what’s driving the selloff?
Neutral Sentiment: Analyst commentary was mixed-to-supportive but still trimmed valuation targets: Cantor Fitzgerald cut its target to $61 from $67 and maintained an overweight rating, while Canaccord Genuity lowered its target to $60 from $62 and kept a buy rating. Benzinga analyst updates
Neutral Sentiment: Guggenheim also raised its price target to $100, suggesting some analysts still see substantial long-term upside despite the clinical setback. Guggenheim Boosts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $100.00

Celldex Therapeutics Company Profile

(Get Free Report)

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.